Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic HER2-mutated NSCLC By Ogkologos - November 14, 2025 323 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SOHO-01 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Activity and Safety of Regorafenib Plus Nivolumab in First-Line Treatment for... February 22, 2024 FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for Large B-Cell Lymphoma April 29, 2021 Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer April 7, 2026 Co-Existing with COVID-19: Should I go back to work? Do I... June 19, 2020 Load more HOT NEWS What’s at the Root of Ovarian Cancer? New Study May Have... Androgen Receptor Pathway Inhibitors Outperform Taxanes in Patients with mCRPC with... Asciminib Shows Superior Efficacy Over Investigator-Selected TKIs and Imatinib in Patients... Woman Battles Breast Cancer While Pregnant, Delivers Healthy Baby Boy
